Long-Term Data Support Stereotactic Body Radiotherapy for Centrally Located NSCLC
The findings further validate the initial 2015 findings that a five-fraction SBRT schedule is appropriate for patients with centrally located NSCLC.
Percentage of Patients to Benefit From Immune Checkpoint Inhibitors Still Limited
The percentage of patients with cancer eligible to receive immune checkpoint inhibitors has increased in recent years, but how many patients are actually responding?
Can Social and Environmental Factors Cause Cancer Disparities?
Cancer Network spoke with Dr. Scarlett Lin Gomez about the role gender, socioeconomic status, race/ethnicity, and neighborhood characteristics have on health outcomes in cancer.
Early Results for Next-Generation TRK Inhibitor LOXO-195 Look “Very Promising”
The investigators tested the agent in patients who had solid tumors with NTRK gene fusions that had developed resistance to other TRK inhibitors.
For Advanced Sarcoma, Adding Lymphodepletion to HER2-Targeted CAR T-Cell Therapy Excites
A phase I trial evaluated the safety and efficacy of adding lymphodepletion to HER2-targeted T-cell therapy in patients with advanced HER2-positive sarcoma.
10 Recent Oncology Drug Approvals
This slideshow summarizes recent US Food and Drug Administration approvals of new oncology drugs and oncology drug indications.
Examining Opioid-Related Hospitalizations for Patients With Cancer
Researchers looked at the trends and risk factors for opioid-related hospitalizations among patients with cancer.
Adopting Clinician Training to Prompt Comprehensive End-of-Life Conversations
A series of communication-focused interventions were implemented to try to improve conversations about values, goals, and preferences with patients with life-limiting cancer.
Role of Chemopreventive Agents in Women at Increased Risk for Breast Cancer
Cancer Network spoke with Charles Shapiro, MD, about the USPSTF's stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer.
A Look at the Clinical Benefits of the FDA’s Expanded Access Program
A single-center evaluation of the FDA's Expanded Access program indicated broad use of the program among the center’s patients, including a large percentage of pediatric patients.
CASSINI Trial Assesses Rivaroxaban for Thromboprophylaxis in Cancer Patients
In a phase IIIb trial, researchers evaluated the efficacy of an oral anticoagulant in cancer patients at high risk for venous thromboembolism.
Study Examines Safety of Immune Checkpoint Inhibitor Therapy in Patients With HIV
A systematic review in JAMA Oncology examined the safety and efficacy of immune checkpoint inhibitors in advanced-stage cancer patients with HIV infection.
Bias for Patient-Reported Outcomes in Open-Label Cancer Trials: How Big of a Concern Is It?
The US Food and Drug Administration explored the possibility of such bias in a recent viewpoint published in JAMA Oncology.
Decreasing Clinical Trial Participation Barriers
Cancer Network speaks with Joseph Unger, PhD, about ways to decrease the barriers for cancer patients to enroll in clinical trials.
Exercise Effects on Depressive Symptoms in Cancer Patients
Cancer Network speaks with an exercise physiologist about the benefits of physical activity for depressed and anxious cancer patients.
Certain Factors Impact Treatment Selection in Advanced Prostate Cancer
Do race, income level, geographic location, and type of specialist influence treatment of metastatic castration-resistant prostate cancer?
Are Germline DNA Repair Mutations Linked to Outcomes in mCRPC?
A new study published in the Journal of Clinical Oncology reported on the clinical implications of gDDR genes.
The Microbiome and Colorectal Cancer: Current Clinical Trials
Here, we look at the currently open and recruiting clinical trials that focus on the role of the microbiome in colorectal cancer.
Cell-Cell Communication in the Tumor Microenvironment
Cancer Network speaks with Peter Ruvolo, PhD, about his work investigating the role of microenvironments in cancer and treatment resistance.
Variant Identified for Testicular Cancer Signals Heightened Risk for Later Cancers
Researchers identified two germline pathogenic variants in CHEK2 that may account for a minority of men diagnosed with testicular germ cell tumors.
Novel Genetic Marker in Ovarian, Lung Cancers
Two new studies found that targeting the cyclin-dependent kinases 4/6 exposed a vulnerability in SMARCA4-deficient cancers.
Oncologists Seek Education on Health Needs of LGBTQ Patients
A recent study showed oncologists lack knowledge, but are interested in receiving additional training to learn about the healthcare needs of LGBTQ patients.
Potential Surrogate Endpoint in Prostate Cancer to Speed Up Clinical Trials
An analysis of a large, phase III trial investigated a potential surrogate endpoint for survival outcomes in prostate cancer patients receiving ADT.
New Biomarker Recognized For Colorectal Cancers
A recent study identified a new biomarker in colorectal cancers that may assist in early detection of the disease.
HPV Gene Expression Signatures, Prognosis in Cervical Cancers
Cancer Network spoke with Curtis Pickering, PhD, about prognostic gene expression signatures for HPV-positive oropharyngeal and cervical cancers.
Study Investigates Survival Rates in Patients with Medullary Thyroid Carcinoma
Researchers conducted the first population-based study of an unselected MTC cohort compared with the general population.
Utilizing US Features and BRAFV600E Mutation Status to Stratify Papillary Thyroid Carcinoma
Clinicians may be able to utilize this information as an effective preoperative tool to stratify risk and determine an initial surgical approach for patients with PTC.
Does Vitamin D Have a Role in Cancer Prevention?
Cancer Network spoke with Dr. Michael Holick about the role of and effectiveness of vitamin D in cancer prevention.
BRAF, MEK Inhibitors Offer Promise in Biliary Tract Cancer
Researchers tested the combination of dabrafenib and trametinib in a phase II trial of patients with biliary tract cancer and BRAF V600E mutations.
Are Response Rates Predictive of Survival Outcome in HCC?
An analysis found that tumor response as assessed using modified RECIST criteria is an independent predictor of overall survival in hepatocellular carcinoma patients.
